BeOne Medicines (ONC) PT Raised to $445 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ONC Hot Sheet
Price: $382.27 -1.08%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Join SI Premium – FREE
JPMorgan analyst Jessica Fye raised the price target on BeOne Medicines (NASDAQ: ONC) to $445.00 (from $425.00) while maintaining a Overweight rating.
You May Also Be Interested In
- BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
- Six Flags Entertainment (FUN) PT Lowered to $14 at Citizens - 'One of the Worst-Performing' Consumer Stocks
- Meta Platforms Inc. (META) PT Raised to $850 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
